What To Do If You Were Sold Cytori Therapeutics Inc. (CYTX) Investments By Your Laidlaw Broker

Stoltmann Law Offices is interested in hearing from those individuals who may have been recommended or sold Cytori Therapeutics Inc. (CYTX) securities by their Laidlaw and Company broker. Laidlaw was also the underwriter of the offering. Newly issued securities tend to be more volatile than older, more established companies, and your broker must disclose the risk to you on every investment he recommends or sells. According to its website and Yahoo Finance, CYTX, which is headquartered in San Diego, California, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various research medical conditions. It also sells Celution cell processing systems, StemSource cell and tissue banking systems, and surgical accessories and instruments to hospitals, clinics, physicians, researchers and other customers for commercial and research purposes through a combination of direct sales force, third-party distributors, independent sales representatives and licenses. It operates in the Americas, Japan, EMEA, and the Asian Pacific.
Laidlaw and Company has a duty to reasonably supervise its brokers in order to ensure that they do not violate securities laws or internal firm rules. If Laidlaw does not, it may be liable for investment losses on a contingency fee basis. We are securities attorneys who sue brokerage firms like Laidlaw and Company. Brokers at Laidlaw and Company must take into account certain factors such as a customer’s age, net worth, investment objectives and portfolio risk tolerance, among other things before recommending investments such as CYTX. The investment may not be suitable for all investors because of these factors.